Skip to menu Skip to content Skip to footer
Associate Professor Jakob Begun
Associate Professor

Jakob Begun

Email: 

Overview

Background

Associate Professor Jakob Begun is the IBD Group leader in the Immunity, Infection, and Inflammation Program at Mater Research University of Queensalnd, and has a basic and translational laboratory at the Translational Research Institute in Brisbane. He is an Associate Professor in the University of Queensland Faculty of Medicine. After completing his Bachelor of Science at Cornell University Jakob attended Cambridge University where he completed an MPhil in Biochemistry. He then moved on to Harvard Medical School where he completed his MD and PhD in genetics studying the host pathogen interaction using C. elegans as a model system. He completed his clinical training in internal medicine at Brigham and Women’s hospital and went on to complete general gastroenterology training at Massachusetts General Hospital (MGH) as well as advanced training in the treatment of Inflammatory Bowel Disease (IBD).

Dr Begun first joined Mater Research - University of Queensland in 2014, and at the same time received a clinical staff appointment in Gastroenterology at the Mater Hospital Brisbane. His clinical activities are focussed on the treatment and mangement of patients with IBD. He is the director of the IBD unit at the Mater Hospital Brisbane and at the Mater Young Adult Health Centre Brisbane .In January 2015 he was awarded the University of Queensland Reginald Ferguson Fellowship in Gastroenterology to support his research activity. He leads a basic and translational laboratory at the Translational Research Institute investigating the interaction between the innate immune system and the gut microbiome, as well as genetic contributions to disease. He also performs clinical research examining predictors of response to therapy, minimising barriers of care for adolescents and young adults with IBD, improving outcomes in pregnancy and IBD, and the use of intestinal ultrasound in IBD. He is the chair of the Gastroenterology Society of Australia-IBD Faculty and of the president of the Gastroenterology Network of Intestinal Ultrasound (GENIUS).

Availability

Associate Professor Jakob Begun is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Biology, Cornell University
  • Doctoral Diploma of Medicine, Harvard University
  • Doctor of Philosophy of Genetics, Harvard University
  • Member, Gastroenterological Society of Australia, Gastroenterological Society of Australia
  • Fellow, Royal Australasian College of Physicians, Royal Australasian College of Physicians

Research impacts

Inflammatory bowel disease(IBD) is a complex disease with genetic and environmental triggers. The microbiota is one of the biggest environmental contributors and interest in its impact on human health and disease is a growing. Studies in IBD have led the way in identifying disease associated microbial signals, but has not yet led to any new therapies.

As a clinician-scientist I am driven by my patients’ needs to address all aspects of their disease: including genetic and environmental risk factors, disease monitoring, and developing novel therapeutics. My tranlsational research program contributes to KNOWLEDGE IMPACT by discovering the function of IBD-susceptibility genes and anti-inflammatory bio-actives produced by the gut microbiota. My clinical research program advances HEALTH IMPACT by optimizing patient monitoring through evidence-based use of biochemical tests and imaging technology.

-Knowledge Impact. My research into the interaction between IBD susceptibility genes and bacterial handling has been highly cited, and led to an NHMRC collaborative project grant.

-Health Impact. My research program into advances in patient monitoring has led to the application for faecal calprotectin testing to be covered by the Medicare Benefit Scheme – which will have a direct impact on patient monitoring in the clinic. Additionally my monitoring research into the use of intestinal ultrasound has led to the formation of the Gastroenterology Network of Intestinal Ultrasound and the increase in ultrasound use in IBD patients in Australia.

Works

Search Professor Jakob Begun’s works on UQ eSpace

182 works between 1996 and 2024

61 - 80 of 182 works

2023

Journal Article

Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer

Lyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127

Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer

2023

Conference Publication

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. OXFORD: OXFORD UNIV PRESS.

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

An, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A. and Begun, J. (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. OXFORD: OXFORD UNIV PRESS.

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

2023

Journal Article

An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis

Mortlock, Sally, Lord, Anton, Montgomery, Grant, Zakrzewski, Martha, Simms, Lisa A, Krishnaprasad, Krupa, Hanigan, Katherine, Doecke, James D, Walsh, Alissa, Lawrance, Ian C, Bampton, Peter A, Andrews, Jane M, Mahy, Gillian, Connor, Susan J, Sparrow, Miles P, Bell, Sally, Florin, Timothy H., Begun, Jakob, Gearry, Richard B and Radford-Smith, Graham L. (2023). An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. Journal of Crohn's and Colitis, 17 (2), 277-288. doi: 10.1093/ecco-jcc/jjac121

An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis

2023

Conference Publication

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

An, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. OXFORD: OXFORD UNIV PRESS.

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

An, Y.K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

2023

Conference Publication

Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease

Moniruzzaman, M., Rewatkar, P., Begun, J. and Popat, A. (2023). Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0167

Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease

2023

Conference Publication

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0543

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

2022

Conference Publication

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

Panes, Julian, Loftus, Edward, Lacerda, Ana, Peyrin-Biroulet, Laurent, D’Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid, Liu, Jianzhong, Dubcenco, Elena, Mohamed, Mohamed-Eslam, Feng, Tian and Colombel, Jean-Frederic (2022). Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results. 2022 Advances in Inflammatory Bowel Diseases Annual Meeting, Orlando, FL United States, 5-7 December 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.14309/01.ajg.0000897656.25080.34

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

2022

Journal Article

Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis

Malloy, Reuben, Fernandes, Richard, Begun, Jakob and An, Yoon-Kyo (2022). Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 15 (12) 252140, e252140. doi: 10.1136/bcr-2022-252140

Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis

2022

Conference Publication

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

An,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard , Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

2022

Journal Article

MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis

Sheng, Yong H., Davies, Julie M., Wang, Ran, Wong, Kuan Yau, Giri, Rabina, Yang, Yuanhao, Begun, Jakob, Florin, Timothy H., Hasnain, Sumaira Z. and McGuckin, Michael A. (2022). MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis. Cellular and Molecular Gastroenterology and Hepatology, 14 (4), 789-811. doi: 10.1016/j.jcmgh.2022.06.010

MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis

2022

Journal Article

GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection

Lamba, M., Tiwari, N., Remedios, M., Begun, J., Christensen, B., Bollipo, S. and Devereaux, B. (2022). GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection. Journal of Gastroenterology and Hepatology (Australia), 37 (7), 1400-1401. doi: 10.1111/jgh.15873

GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection

2022

Journal Article

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Sands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B, Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Mihaly, Emese, Panaccione, Remo, Scherl, Ellen, Shchukina, Oksana B, Sandborn, William J, Afzali, Anita, Aitova, Lilia, Aldeguer i Mante, Xavier, Altorjay, István, Argüelles Arias, Federico, Armuzzi, Alessandro, Augustyn, Monika, Bafutto, Mauro, Barrio, Jesus, Begun, Jakob ... Zdena, Zadorova (2022). Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet, 399 (10342), 2200-2211. doi: 10.1016/S0140-6736(22)00688-2

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

2022

Journal Article

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis

Cheon, Jae Hee, Paridaens, Kristine, Awadhi, Sameer Al, Begun, Jakob, Fullarton, John R, Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Dignass, Axel U and Travis, Simon PL (2022). The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 21 (1), 161-167. doi: 10.5217/ir.2022.00006

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis

2022

Journal Article

Secreted NF-κB suppressive microbial metabolites modulate gut inflammation

Giri, Rabina, Hoedt, Emily C., Khushi, Shamsunnahar, Salim, Angela A., Bergot, Anne-Sophie, Schreiber, Veronika, Thomas, Ranjeny, McGuckin, Michael A., Florin, Timothy H., Morrison, Mark, Capon, Robert J., Ó Cuív, Páraic and Begun, Jakob (2022). Secreted NF-κB suppressive microbial metabolites modulate gut inflammation. Cell Reports, 39 (2) 110646, 110646. doi: 10.1016/j.celrep.2022.110646

Secreted NF-κB suppressive microbial metabolites modulate gut inflammation

2022

Journal Article

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Louis, Edouard, Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Dignass, Axel U, Magro, Fernando, Márquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Freddi, Matthew J and Travis, Simon Pl (2022). Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 9 (1) e000853, e000853. doi: 10.1136/bmjgast-2021-000853

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

2022

Journal Article

Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages

Tran, Thao Thanh, Mathmann, Carmen D., Gatica-Andrades, Marcela, Rollo, Rachel F., Oelker, Melanie, Ljungberg, Johanna K., Nguyen, Tam T. K., Zamoshnikova, Alina, Kummari, Lalith K., Wyer, Orry J. K., Irvine, Katharine M., Melo-Bolívar, Javier, Gross, Annette, Brown, Darren, Mak, Jeffrey Y. W., Fairlie, David P., Hansford, Karl A., Cooper, Matthew A., Giri, Rabina, Schreiber, Veronika, Joseph, Shannon R., Simpson, Fiona, Barnett, Timothy C., Johansson, Jörgen, Dankers, Wendy, Harris, James, Wells, Timothy J., Kapetanovic, Ronan, Sweet, Matthew J. ... Blumenthal, Antje (2022). Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathogens, 18 (1) e1010166, e1010166. doi: 10.1371/journal.ppat.1010166

Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages

2022

Journal Article

Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis

Movva, Ramya, Murtaza, Nida, Giri, Rabina, Png, Chin Wen, Davies, Julie, Alabbas, Saleh, Oancea, Iulia, O'Cuiv, Páraic, Morrison, Mark, Begun, Jakob and Florin, Timothy H. (2022). Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis. Gastro Hep Advances, 1 (3), 359-374. doi: 10.1016/j.gastha.2021.12.008

Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis

2021

Journal Article

Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis

Dignass, Axel U., Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Fullarton, John R., Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R., Narula, Neeraj, Rydzewska, Grazyna and Travis, Simon P. L. (2021). Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 57 (4), 1-8. doi: 10.1080/00365521.2021.2015801

Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis

Funding

Current funding

  • 2024 - 2026
    Gut Health anti-inflammatory potential of Yumbah abalone and mussels
    Marine Bioproducts Cooperative Research Centre
    Open grant
  • 2024 - 2027
    Harnessing microbial immunomodulatory function to improve treatment of inflammatory bowel diseases
    NHMRC IDEAS Grants
    Open grant
  • 2023 - 2028
    Immunity, Infection and Inflammation Program at MRI-UQ
    Mater Foundation
    Open grant
  • 2023 - 2025
    Epithelial tissue mechanics: a new key to relapse in chronic inflammatory bowel disease
    United States Congressionally Directed Medical Research Programs - Peer Reviewed Medical Research Program
    Open grant
  • 2023 - 2025
    Understanding the regulation and function of OTUD3, a novel ulcerative colitis gene
    The Gutsy Group Inflammatory Bowel Disease Research Grants
    Open grant
  • 2021 - 2024
    Drugs from Bugs: Developing New Inflammatory Bowel Disease Drugs from Gut Bacteria-Derived Bioactives
    United States Congressionally Directed Medical Research Programs - Peer Reviewed Medical Research Program
    Open grant

Past funding

  • 2020 - 2021
    Functionally characterizing IBD dysbiosis and harnessing gut bioactives to suppress IL-23 driven inflammation
    The Global Grants for Gut Health
    Open grant
  • 2019
    Improving IBD treatment through harnessing the microbiome and improving outcomes in young adults with IBD
    Ferguson Foundation (Reginald Ferguson)
    Open grant
  • 2018 - 2020
    Mater Health Services IBD Biobank
    Research Donation Generic
    Open grant
  • 2018 - 2022
    The regulatory role of Clec12A in antigen presentation and inflammatory disease (NHMRC Project Grant led by Monash University)
    Monash University
    Open grant
  • 2017 - 2020
    Invention of a Genetic Toolkit for Immunomodulatory Gut Bacteria to Expedite the Development of New Crohn's Disease Therapeutics
    United States Congressionally Directed Medical Research Programs - Peer Reviewed Medical Research Program
    Open grant
  • 2017
    Identification of novel genetic causes of ulcerative colitis to inform individualised treatment
    Sylvia and Charles Viertel Charitable Foundation
    Open grant
  • 2015 - 2016
    Improving IBD treatment through an understanding of genetics and obstacles to adolescent care
    Ferguson Foundation (Reginald Ferguson)
    Open grant
  • 2014 - 2015
    Towards an oral IL-22 agonist for ulcerative colitis
    Ferring Research Institute
    Open grant

Supervision

Availability

Associate Professor Jakob Begun is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Microbial Regulation of Host Inflammatory Pathways in Inflammatory Bowel Disease

    Principal Advisor

    Other advisors: Professor Mark Morrison, Dr Anuj Sehgal

  • Doctor Philosophy

    Study of TOfacitinib for the treatment of chronic Pouchitis

    Principal Advisor

    Other advisors: Professor Gerald Holtmann

  • Doctor Philosophy

    Reducing post-operative Crohn's disease recurrence

    Principal Advisor

    Other advisors: Professor David Clark

  • Doctor Philosophy

    A randomised, open-label, non-inferiority study of upadacitinib compared with oral prednisolone

    Principal Advisor

    Other advisors: Dr Paul Clark

  • Doctor Philosophy

    Designer Nanoparticles for Oral and Targeted Delivery of Protein Therapeutics

    Associate Advisor

    Other advisors: Dr Md Moniruzzaman, Associate Professor Amirali Popat

  • Doctor Philosophy

    Defining the Role of the Mucosa-Associated Microbiota in Digestive Health and Disease Using Novel ex-vivo Combinations of Microbe Culture with Metagenomics

    Associate Advisor

    Other advisors: Professor Mark Morrison

  • Doctor Philosophy

    Bacteria x Archaea Interactions in Crohn's disease

    Associate Advisor

    Other advisors: Professor Mark Morrison

  • Doctor Philosophy

    Medicinal chemistry of new Nature-inspired treatments for Inflammatory Bowel Disease (IBD)

    Associate Advisor

    Other advisors: Dr Angela Salim, Dr Zeinab Khalil, Professor Rob Capon

Completed supervision

Media

Enquiries

Contact Associate Professor Jakob Begun directly for media enquiries about:

  • adolescent
  • autophagy
  • Crohn's disease
  • Inflammatory Bowel Disease
  • ulcerative colitis

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au